• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性肺纤维化合并 COVID-19 患者的特征和结局:一项多中心回顾性研究。

Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study.

机构信息

Department of Respiratory Disease, Akdeniz University, Antalya, Turkey.

Department of Respiratory Disease, Cukurova University, Adana, Turkey.

出版信息

Respir Med Res. 2022 May;81:100900. doi: 10.1016/j.resmer.2022.100900. Epub 2022 Mar 3.

DOI:10.1016/j.resmer.2022.100900
PMID:35338917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8890788/
Abstract

BACKGROUND

There are few data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) infection in patients with idiopathic pulmonary fibrosis (IPF). The objective of this study is to describe the characteristics and outcomes of IPF patients confirmed COVID-19 infection.

METHODS

In this retrospective, multi-center, cohort study, patients from 4 hospital medical records with known IPF and a COVID-19 diagnosis were identified. Demographic and clinical outcome data were abstracted through a review of electronic medical records.

RESULTS

Records for 46 patients with IPF and COVID-19 were abstracted. The mean age was 65±10 years. The most common symptom was dyspnea, followed by fever and cough. Ground-glass opacities (n = 35, 83.3%) and consolidations (n = 11, 26.1%) were the main imaging features of the disease in thorax computed tomography (CT). Twenty-four patients (52.1%) required hospitalization. Among the hospitalized patients, 16 (66.6%) were admitted to the intensive care unit (ICU), and 10 (41.6%) underwent invasive mechanical ventilation. Thirteen patients (28.2%) died of COVID-19 complications. Mortality rate was significantly associated with lower DLCO/VA, long term oxygen therapy and consolidation finding on CT of thorax (p<0.05). On multivariable analysis, neither factor was associated with hospitalization or mortality.

CONCLUSIONS

IPF patients represent a vulnerable population for COVID-19, according to the high rate of hospitalization, ICU requirement, and mortality rate. Measures to minimize the risk of COVID-19 infection remain key to protect IPF patients.

摘要

背景

关于特发性肺纤维化(IPF)患者严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)(COVID-19)感染的数据很少。本研究的目的是描述确诊 COVID-19 感染的 IPF 患者的特征和结局。

方法

在这项回顾性、多中心队列研究中,从 4 家医院的病历中确定了已知患有 IPF 和 COVID-19 的患者。通过审查电子病历,提取人口统计学和临床结局数据。

结果

共提取了 46 例 IPF 和 COVID-19 患者的记录。平均年龄为 65±10 岁。最常见的症状是呼吸困难,其次是发热和咳嗽。肺部计算机断层扫描(CT)的主要影像学特征是磨玻璃影(n=35,83.3%)和实变(n=11,26.1%)。24 例患者(52.1%)需要住院治疗。在住院患者中,16 例(66.6%)入住重症监护病房(ICU),10 例(41.6%)接受有创机械通气。13 例患者(28.2%)死于 COVID-19 并发症。死亡率与较低的 DLCO/VA、长期氧疗和胸部 CT 实变发现显著相关(p<0.05)。多变量分析显示,没有一个因素与住院或死亡率相关。

结论

根据住院、入住 ICU 和死亡率高的情况,IPF 患者是 COVID-19 的高危人群。最大限度地降低 COVID-19 感染风险的措施仍然是保护 IPF 患者的关键。

相似文献

1
Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study.特发性肺纤维化合并 COVID-19 患者的特征和结局:一项多中心回顾性研究。
Respir Med Res. 2022 May;81:100900. doi: 10.1016/j.resmer.2022.100900. Epub 2022 Mar 3.
2
Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis.特发性肺纤维化患者感染 COVID-19 后临床结局较差:一项倾向评分匹配的多中心研究网络分析。
BMJ Open Respir Res. 2021 Aug;8(1). doi: 10.1136/bmjresp-2021-000969.
3
Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis.因特发性肺纤维化入住重症监护病房患者的治疗结果。
Crit Care Resusc. 2009 Jun;11(2):102-9.
4
Infectious respiratory pathogens among patients with acute exacerbation of idiopathic pulmonary fibrosis during the coronavirus disease 2019 pandemic in Japan.在 2019 冠状病毒病大流行期间,日本特发性肺纤维化急性加重患者中的感染性呼吸道病原体。
Heart Lung. 2024 Sep-Oct;67:1-4. doi: 10.1016/j.hrtlng.2024.03.007. Epub 2024 Apr 2.
5
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
6
Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis: A case-control study.COVID-19 后肺纤维化的临床特征和结局:一项病例对照研究。
Medicine (Baltimore). 2022 Jan 21;101(3):e28639. doi: 10.1097/MD.0000000000028639.
7
Impact of the coronavirus disease 2019 pandemic on hospital admissions for idiopathic pulmonary fibrosis: a nationwide population-based study.2019 冠状病毒病大流行对特发性肺纤维化住院的影响:一项全国性基于人群的研究。
BMC Pulm Med. 2024 Aug 31;24(1):430. doi: 10.1186/s12890-024-03230-3.
8
The characteristics and outcomes of patients with idiopathic pulmonary fibrosis admitted to the ICU with acute respiratory failure.特发性肺纤维化患者因急性呼吸衰竭入住 ICU 的特征和结局。
Heart Lung. 2021 Jan-Feb;50(1):192-196. doi: 10.1016/j.hrtlng.2020.05.006. Epub 2020 Jun 8.
9
COVID-19 Severity and Mortality in Veterans with Chronic Lung Disease.慢性肺部疾病退伍军人的 COVID-19 严重程度和死亡率。
Ann Am Thorac Soc. 2024 Jul;21(7):1034-1043. doi: 10.1513/AnnalsATS.202311-974OC.
10
COVID-19 outcomes of patients with gynecologic cancer in New York City.纽约市妇科癌症患者的 COVID-19 结局。
Cancer. 2020 Oct 1;126(19):4294-4303. doi: 10.1002/cncr.33084. Epub 2020 Jul 30.

引用本文的文献

1
Hematologic and Immunologic Overlap Between COVID-19 and Idiopathic Pulmonary Fibrosis.新型冠状病毒肺炎与特发性肺纤维化之间的血液学和免疫学重叠
J Clin Med. 2025 Jul 24;14(15):5229. doi: 10.3390/jcm14155229.
2
Clinical impacts of COVID-19 on severe exacerbation and mortality in interstitial lung disease: prognosis 30 days after infection.新型冠状病毒肺炎对间质性肺疾病严重加重和死亡率的临床影响:感染后30天的预后
Korean J Intern Med. 2025 Jul;40(4):634-644. doi: 10.3904/kjim.2024.388. Epub 2025 Jul 1.
3
Clinical impact of idiopathic pulmonary fibrosis on SARS-CoV-2 patient outcomes: a comprehensive analysis in the pre-vaccination era.特发性肺纤维化对感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)患者预后的临床影响:疫苗接种前时代的综合分析
Front Med (Lausanne). 2025 May 21;12:1567232. doi: 10.3389/fmed.2025.1567232. eCollection 2025.
4
Overlapping Systemic Proteins in COVID-19 and Lung Fibrosis Associated with Tissue Remodeling and Inflammation.新冠病毒肺炎和与组织重塑及炎症相关的肺纤维化中的重叠系统性蛋白质
Biomedicines. 2024 Dec 19;12(12):2893. doi: 10.3390/biomedicines12122893.
5
Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation.真实世界研究:尼马曲韦-利托那韦或莫努匹拉韦在有慢性呼吸系统疾病且初次就诊时为中度 COVID-19 的未接种疫苗住院患者中的疗效。
Int J Chron Obstruct Pulmon Dis. 2024 Jan 9;19:77-86. doi: 10.2147/COPD.S440895. eCollection 2024.
6
Long-Term Radiological Pulmonary Changes in Mechanically Ventilated Patients with Respiratory Failure due to SARS-CoV-2 Infection.新型冠状病毒肺炎(SARS-CoV-2)感染致呼吸衰竭机械通气患者的长期肺部影像学改变
Biomedicines. 2023 Sep 26;11(10):2637. doi: 10.3390/biomedicines11102637.
7
Frequency of subclinical interstitial lung disease in COVID-19 autopsy cases: potential risk factors of severe pneumonia.COVID-19 尸检病例中亚临床间质性肺病的频率:重症肺炎的潜在危险因素。
BMC Pulm Med. 2023 Oct 27;23(1):408. doi: 10.1186/s12890-023-02692-1.
8
Mortality in patients with interstitial lung diseases hospitalized by severe or critical COVID-19.因重症或危重症新型冠状病毒肺炎住院的间质性肺疾病患者的死亡率
BMC Pulm Med. 2023 Oct 13;23(1):388. doi: 10.1186/s12890-023-02697-w.
9
Longitudinal Analysis of Pulmonary Function Impairment One Year Post-COVID-19: A Single-Center Study.新冠病毒感染后一年肺功能损害的纵向分析:一项单中心研究
J Pers Med. 2023 Jul 26;13(8):1190. doi: 10.3390/jpm13081190.
10
A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study.一项关于尼达尼布治疗特发性肺纤维化患者的波兰经验的真实世界多中心回顾性观察研究:PolExNIB研究。
J Clin Med. 2023 Jul 12;12(14):4635. doi: 10.3390/jcm12144635.

本文引用的文献

1
Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis.特发性肺纤维化患者感染 COVID-19 后临床结局较差:一项倾向评分匹配的多中心研究网络分析。
BMJ Open Respir Res. 2021 Aug;8(1). doi: 10.1136/bmjresp-2021-000969.
2
Interstitial lung disease increases susceptibility to and severity of COVID-19.间质性肺疾病增加了感染 COVID-19 的易感性和严重程度。
Eur Respir J. 2021 Dec 2;58(6). doi: 10.1183/13993003.04125-2020. Print 2021 Dec.
3
Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19.颗粒物上调 ACE2 和 TMPRSS2 与特发性肺纤维化:在严重 COVID-19 中的潜在作用。
Part Fibre Toxicol. 2021 Mar 11;18(1):11. doi: 10.1186/s12989-021-00404-3.
4
Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease.患有间质性肺疾病的COVID-19患者死亡的危险因素
Am J Respir Crit Care Med. 2021 Jan 15;203(2):245-249. doi: 10.1164/rccm.202007-2638LE.
5
COVID-19 and Interstitial Lung Disease: Keep Them Separate.新型冠状病毒肺炎与间质性肺疾病:加以区分
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1614-1616. doi: 10.1164/rccm.202010-3918ED.
6
Angiotensin-converting enzyme 2 expression in COPD and IPF fibroblasts: the forgotten cell in COVID-19.COPD 和 IPF 成纤维细胞中的血管紧张素转换酶 2 表达:COVID-19 中被遗忘的细胞。
Am J Physiol Lung Cell Mol Physiol. 2021 Jan 1;320(1):L152-L157. doi: 10.1152/ajplung.00455.2020. Epub 2020 Oct 28.
7
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study.间质性肺疾病患者 COVID-19 住院治疗结局。一项国际多中心研究。
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1656-1665. doi: 10.1164/rccm.202007-2794OC.
8
Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study.间质性肺疾病合并新型冠状病毒肺炎患者死亡几率增加:一项病例对照研究
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1710-1713. doi: 10.1164/rccm.202006-2441LE.
9
A Fatal Case of Coronavirus Disease 2019 (COVID-19) in a Patient With Idiopathic Pulmonary Fibrosis.一例特发性肺纤维化患者的新型冠状病毒肺炎(COVID-19)致死病例
Cureus. 2020 Jun 3;12(6):e8432. doi: 10.7759/cureus.8432.
10
Clinical characteristics of COVID-19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan, China.COVID-19 患者中合并间质性肺病的临床特征:来自中国武汉单中心的回顾性研究。
J Med Virol. 2020 Nov;92(11):2742-2750. doi: 10.1002/jmv.26174. Epub 2020 Aug 2.